Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of LP-003 in moderate-to-severe persistent allergic asthma
CTR20243191Phase 2Active
- Sponsor
- LongBio Pharma
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LP-003 in allergic asthma, sponsored by LongBio Pharma. Started Jan 2025; status: active.
02
Drugs
LP-003
03
Conditions
allergic asthma
Beyond the preview
Go deeper on CTR20243191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243191.